Abstract
SAGE Publications wish to apologise for the following error which was introduced into “GLP-1 receptor agonists: a review of head-to-head clinical studies” by Jennifer M. Trujillo, Wesley Nuffer and Samuel L. Ellis. This article was published in Therapeutic Advances in Endocrinology and Metabolism 2015, volume 6(1) 19–28, DOI: 10.1177/2042018814559725.
Unfortunately when the figures were updated the captions were not. SAGE is extremely sorry for the inconvenience this error will cause to the authors and the readers. The correct figures and captions have been reproduced below.
Figure 1.
Change in A1C values with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in head-to-head clinical studies.
p-values are for statistical superiority unless otherwise noted as non-inferiority; * p < 0.0025, † p < 0.0001, ‡ p =0.02, § p = not significant, noninferiority p-value not reported (95% confidence interval 0.033-0.297, meeting predefined non-inferiority margin), ¶ non-inferiority p-value=0.0846 (not meeting predefined non-inferiority margin), **p<0.001 for both doses of dulaglutide versus exenatide bid, †† p= not significant, non-inferiority p-value < 0.0001 (meeting predefined non-inferiority margin).
Figure 2.
Change in weight with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in head-to-head clinical studies.
p-values are for statistical superiority (unless noted for non-inferiority); * p = not significant, † p = 0.0005, ‡ p-value not reported for weight difference of 1.02 kg (95% confidence interval 0.456-1.581), § p < 0.0001, ¶ p < 0.001 dulaglutide 0.75mg versus exenatide bid, ** p = not significant between dulaglutide 1.5mg versus exenatide bid,†† p = 0.011.